pegylated interferon-alpha-2a
Phase 3Small molecule
AstraZenecapegylated interferon-alpha-2a is one of 109 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 3.
4
Indications
13
Total Trials
0
Active Trials
108
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Leukine
SanofiPhase 3
Tecentriq
RochePhase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Libtayo
RegeneronPhase 3
Imjudo
AstraZenecaPhase 3
Tuoyi
SSun Yat-sen University
Phase 3
Incomplete Freund's Adjuvant
EEastern Cooperative Oncology Group
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Epacadostat
IncytePhase 3
pegylated interferon-alpha-2a
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis6 trials
Show 3 more trials
Hepatitis C2 trials
2 more indications
TED1 trial
Efficacy and Safety1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company